Current Scenario of Pyridine/Quinoline-Sulfonamide Hybrids with Anticancer Potential (A Review)

This is the authors' abstract. We don't add key points for this paper.

Cancer, which proliferates and spreads uncontrollably due to the accumulation of genetic and epigenetic factors, is one of the most fatal diseases. Cancer management meets multiple obstacles, and resistance to current therapeutic approaches is the major one. Pyridines/quinolines and sulfonamides can exert the anticancer potential through different mechanisms, and many current available anticancer chemotherapeutics own a pyridine/quinoline or sulfonamide moiety, revealing that pyridine/quinoline and sulfonamide motifs are useful pharmacophores for the discovery of novel anticancer agents. Notably, incorporation of pyridine/quinoline and sulfonamide pharmacophores into one molecule is a promising strategy to overcome drug resistance, improve the activity and reduce the toxicity since pyridine/quinoline-sulfonamide hybrids could simultaneously act on dual/multiple targets in cancer cells. This review outlines the current scenario of pyridine/quinoline-sulfonamide hybrids with the anticancer potential, covering articles published from 2020 onwards, to pave the way for the development of novel more effective and multitargeted anticancer candidates.